As this year’s Nobel Prize winners were walking into Stockholm City Hall for festivities recently, the temperature was climbing below zero in the December night outside.

The post A New Dawn For Data appeared first on NLS.

Journalist and documentary filmmaker Luis Jachmann has visited North Sweden to document Umeå’s role as a life science hub.

The post Life sciences in Umeå is highlighted in new documentary appeared first on NLS.

BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology. 

The post BioArctic enters global license agreement with Bristol Myers Squibb appeared first on NLS.

Novo Nordisk has announced plans to establish a completely new production facility in Odense, Denmark.

The post Novo Nordisk invests DKK 8.5 billion in new production facility appeared first on NLS.

Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.

The post Ultimovacs combines its business with Zelluna Immunotherapy appeared first on NLS.

Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.

The post Hansa Biopharma announces positive full results appeared first on NLS.

The PrimaryBid Offering attracted strong interest from both new and existing investors, with participation from over 200 retail investors across Norway, Denmark and Finland.

The post Lytix raises more than NOK 110 million through a directed issue and private issue to retail investors appeared first on NLS.

Orexo has recently entered a settlement agreement with Sun Pharmaceuticals Industries to resolve a patent litigation regarding the company's Zubsolv sublingual tablet for the treatment of opioid use disorder in the US. NLS asked Nikolaj Sørensen, CEO of Orexo, about the impact of this settlement and his thoughts on the patent litigation process and generic challenges.

The post Q&A Orexo: Patent litigation appeared first on NLS.

Orexo has entered into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology.

The post Orexo and Abera collaborate appeared first on NLS.

With just months to go before the EU joint clinical assessment (JCA) process takes effect, the focus on what it will mean from a country perspective is intensifying.

The post Key takeaways from the EU HTA panel discussion in Finland appeared first on NLS.